Transferring a marketing authorisation in the EU: procedure, documents and timelines

A transfer of a marketing authorisation moves the authorisation, and every obligation attached to it, from one legal entity to another. For centrally authorised products the procedure is set by Commission Regulation (EC) No 2141/96 and runs through the European Medicines Agency (EMA) in 30 days.

Read more about what this guide covers

For national, mutual recognition and decentralised authorisations there is no EU procedure at all: each Member State handles the transfer under its own rules. This guide covers what counts as a transfer, both routes, the document set, what the new holder needs in place on the transfer date, the packaging changeover, and how to plan a transfer across many markets.

16 min readUpdated 13 primary sources

Reviewed by Gosia Luksza, CEO at Regunaut

Key figures
for EMA's opinion, counted from receipt of a valid application (Article 4)
30 days
marketing authorisation per transfer application (Article 3)
1
maximum transitional period between the Commission decision and the implementation date
6 months
to update the Article 57 database after the transfer is approved
30 days

In short

  • A transfer is a change of legal entity. A new name or address for the same entity is a Type IA IN variation, not a transfer.
  • Centralised products follow Regulation (EC) No 2141/96: one application per authorisation, an EMA opinion within 30 days, then a Commission decision.
  • National, MRP and DCP authorisations are transferred country by country under national rules, so the dates, forms and fees differ in each Member State.
  • The new holder needs its EEA establishment, QPPV and pharmacovigilance system in place on the transfer date, and the packs must follow within the transition period each authority allows.

Each section opens with its main point. Open the ones you need.

What a transfer is, and what it is not

Article 2 of Regulation (EC) No 2141/96 defines a transfer as the procedure that changes the addressee of the marketing authorisation decision, the new holder not being the previous holder. EMA's guidance puts the same test in plainer words: the authorisation passes from the current holder, the transferor, to a different person or legal entity, the transferee. Typical causes are the sale of a product, a merger in which the old holder ceases to exist, and a group reorganisation that moves licences from one subsidiary to another. A transfer within a group is still a transfer, because the two subsidiaries are different legal entities.

Read more about What a transfer is, and what it is not

The distinction matters because transfers sit outside the variations system. Article 1(2) of Regulation (EC) No 1234/2008 states that the Variations Regulation does not apply to transfers of a marketing authorisation from one holder to another. A change in the name or address of the holder, where the legal entity stays the same, is the opposite case: it is a variation, and a simple one. Our guide to classifying variations covers the categories; the table shows where the changes that surround a transfer belong.

Changes around a change of holder and how each is filed
ChangeWhat it isHow it is filed
The authorisation moves to a different legal entityTransferCentralised: application under Regulation (EC) No 2141/96. National, MRP and DCP: national transfer application in each Member State.
Same legal entity, new name or addressVariationType IA IN, category E.4(a) of the 2025 classification guidelines, filed through the normal variation route.
Holder and local representative details in the SmPC, leaflet and labellingPart of the transferIncluded in the transfer application; no other product information changes may ride along.
Product name that contains the old holder's nameVariationSeparate variation in category E.1, submitted in parallel with the transfer and cross-referenced to it.
New pharmacovigilance system summaryDepends on the routeCentralised: notified within the transfer application. MRP and DCP: Type IA IN variation C.8(a) to all Member States concerned.
New manufacturing or batch release siteVariationSeparate variation, handled independently of the transfer.

The test is the legal entity, not the letterhead

The applicant has to determine and declare whether the legal entity remains the same and only changes its name, or whether a different entity takes over. A rebranding after an acquisition is a variation if the registered entity survives; a merger that dissolves the registered holder is a transfer, even if nothing changes on the pack except the address.

Centralised products: Regulation (EC) No 2141/96

For a centrally authorised product the current holder applies to EMA, with the documents listed in the Annex to the regulation and the fee. Article 3 allows an application to cover one marketing authorisation only, so a portfolio deal means one application per authorisation, although EMA accepts a common data package across them. EMA asks the transferor to make contact at least one month before submission, and since January 2025 transfers are managed through its IRIS platform alongside the eCTD submission. There are no fixed submission dates.

  1. Before

    Pre-submission contact and document set

    The transferor contacts EMA at least one month ahead. Both parties sign the declarations, the transferee assembles its pharmacovigilance documents, and the product information and mock-ups are revised with the new holder's details in every language.

  2. Day A

    Valid application received

    EMA checks completeness within seven days. If documents are missing or incorrect, the applicant has ten calendar days to respond through eCTD. No favourable opinion is issued on incomplete documentation.

  3. Within 30 days

    EMA opinion

    The opinion goes to the transferor, the transferee and the Commission. Under Article 5 it can be unfavourable on two grounds only: the documents are incomplete, or the new holder is not established in the Community, which today means the EEA.

  4. Day B

    Commission decision notified

    The Commission amends the marketing authorisation decision. Under Article 7 the transfer is authorised from the date the amended decision is notified; the transferee is the holder and EMA's contact from that day.

  5. Day C

    Implementation date

    The date, agreed with EMA and stated in the opinion and the decision, on which the transferee takes over all responsibilities. For a marketed product it may fall up to six months after Day B; for a product not yet marketed it is tied to the decision.

The procedure is administrative. EMA does not reassess quality, safety or efficacy, and the transfer does not affect the time limits attached to the authorisation, so the renewal date stays where it was (Article 7(3)). After the decision the Commission publishes the change in the Union Register and EMA revises the European public assessment report to show the new holder. If the product has an orphan designation, the designation is transferred separately under Article 5(11) of Regulation (EC) No 141/2000, ideally at the same time, with each cover letter referring to the other.

National, MRP and DCP products: one transfer per Member State

Directive 2001/83/EC contains no transfer procedure, and because Article 1(2) of the Variations Regulation excludes transfers, the mutual recognition machinery does not apply either. The CMDh states the consequence in its questions and answers on variations: the transfer of an authorisation to a new holder is handled as an independent, purely national application, the fees are set by each concerned Member State, and each concerned Member State manages its own procedure. The role of the reference Member State is limited: the current holder sends it a notification saying which concerned Member States and which holders the national procedures involve.

Read more about National, MRP and DCP products: one transfer per Member State

National procedures share a pattern even though the forms differ. The application usually comes from the current holder, with a declaration from each party, proof that the new holder is established in the EEA, the revised SmPC, package leaflet and labelling, mock-ups where the authority reviews them, details of the local representative and the pharmacovigilance arrangements the Member State requires, and a fee per authorisation. Two published examples show the range. The Dutch Medicines Evaluation Board accepts an application from either party, the future holder needing a letter of authorisation from the current one, allows no other changes in the same application, and processes a change of holder within 60 days without guaranteeing a specific date. The Croatian agency HALMED requires the current holder to apply, keeps the original expiry date of the authorisation, and lets stock released under the previous holder stay on the market for up to 18 months, shelf life permitting.

One part of an MRP or DCP transfer does run at European level. The CMDh requires the new holder's summary of the pharmacovigilance system to be submitted to all Member States concerned through an MRP variation, as a Type IA IN notification in category C.8(a). The variation is not needed where the authorisation moves between companies of the same parent and the same pharmacovigilance system master file continues to be used. A product name change triggered by the transfer is likewise a variation at MRP level, filed in parallel with the national transfer applications.

There is no common transfer date

National approvals arrive on different days, and several authorities will not commit to a date in advance. For a period the same MRP or DCP product has the old holder in some Member States and the new holder in others. The pharmacovigilance agreement between the two companies, the variation plan and the artwork schedule all have to work country by country during that period.

The document set

The Annex to Regulation (EC) No 2141/96 lists six items for a centralised transfer, the first four signed by both parties, and EMA's guidance explains how to present them in Module 1 of the eCTD. National lists follow the same logic, with local additions.

Documents for a transfer application
DocumentCentralised (Annex to Regulation 2141/96, EMA guidance)National pattern
Authorisation and partiesProduct name, authorisation numbers and grant dates; name and address of both holders.Product name and national authorisation number, with a list where many products move; contact details of both parties.
DeclarationsCertification that the complete, up-to-date file has been made available to the new holder, and the date on which it can take over all responsibilities.The current holder's consent and the new holder's declaration that it takes over all rights and obligations.
EstablishmentProof that the transferee is established in the EEA, no more than six months old.Proof of establishment in the EEA.
Capacity of the new holderThe QPPV with contact details, the pharmacovigilance system summary in the transferee's name, and the scientific service in charge of information about the product.Pharmacovigilance and local contact arrangements as national law requires; the system summary by variation for MRP and DCP products.
CommitmentsA signed undertaking to complete remaining post-authorisation measures, and a statement that only holder and local representative details change in the product information.A declaration that only the holder details, and the name where relevant, change.
Product information and mock-upsSmPC, labelling and leaflet with the new holder in all EU languages plus Icelandic and Norwegian, tracked and clean; mock-ups of outer and immediate packaging.Revised national texts, clean and tracked, with mock-ups where requested.
FeeThe transfer fee under the EMA fee regulation.A national fee, typically per authorisation.

EMA also asks for the proposed implementation date and the transitional arrangements as a separate attachment, including when the transferor expects to release its last batch. That attachment is where the six-month ceiling applies, so it should be drafted with the artwork and supply plan in hand, not after it.

What must be in place on the transfer date

From the transfer date the new holder is the marketing authorisation holder in every legal sense. The authorities grant no grace period for the holder's own obligations, so the items below have to be operating on the day, not in progress.

Read more about What must be in place on the transfer date
  • Establishment in the EEA. Article 8(2) of Directive 2001/83/EC allows an authorisation to be granted only to an applicant established in the Community, and lack of establishment is one of the two grounds for refusing a centralised transfer.
  • A pharmacovigilance system. Under Article 104(3) of the directive the holder must have a QPPV permanently and continuously at its disposal, residing and operating in the Union, and must maintain a pharmacovigilance system master file. In practice that means a safety data exchange agreement with the seller and a dated handover of the safety database.
  • Article 57 data. Changes following a transfer must be notified to EMA's Article 57 database (xEVMPD) no later than 30 calendar days from the date the transfer is authorised. Later changes to the QPPV or the master file location are made in the database and need no variation.
  • Pending procedures. EMA advises against variations in parallel with a centralised transfer; if a deadline falls between submission and the Commission decision, the transferor files and the transferee then takes over. Agree an owner for every open procedure before filing.
  • Commitments and safety documents. Post-authorisation measures, the risk management plan, educational materials that name the holder and the PSUR schedule pass to the new holder with the licence.
  • Manufacturing and release. The transfer does not change the manufacturers in the dossier. Agreements with manufacturing and batch release sites are re-signed with the new holder, and a change of site is a separate variation.
  • Supply chain data. Under Article 33 of Delegated Regulation (EU) 2016/161 the holder ensures that unique identifier data are uploaded to the repositories system before a pack is released, so that responsibility moves too.

A transfer also leaves some clocks running. The validity of the authorisation is unchanged, and so is the three-year sunset clause: transferring a dormant licence is not placing the product on the market, so the buyer inherits the time already elapsed. Our guide to renewals and the sunset clause explains how that period is counted.

Product information, packaging and old stock

The holder's name is printed on more components than most plans assume. Article 54(k) of Directive 2001/83/EC requires the name and address of the marketing authorisation holder, and where applicable its representative, on the outer packaging. Article 55 requires the holder's name on blister packs. Article 59(1)(f) requires the holder's name and address, and its representatives in the Member States, in the package leaflet. Section 7 of the SmPC names the holder as well. A transfer therefore touches the carton, the foil or label, the leaflet and the SmPC for every presentation and every language, plus the list of local representatives in a centralised leaflet.

Read more about Product information, packaging and old stock

For centralised products EMA sets out who may release what during the changeover. Until the Commission decision is notified, the transferor is responsible for the batches released. From that date the new holder may release batches and is responsible for all of them, and batches carrying the previous holder's name may still be placed on the market by agreement during the transitional period. After the implementation date only the transferee releases batches; packs already on the market under the old name may remain there. National authorities set their own periods for old stock, as the Croatian 18-month rule shows, so the changeover date for artwork has to be checked market by market.

Three details regularly add work. A product name that includes the holder's name, as many generic names of the form "substance plus company" do, must change, through a separate variation and, for a centralised product, after the Name Review Group has accepted the new name. Web addresses and QR codes in the product information that point to the transferor must be updated by the transferee; EMA expects an Article 61(3) notification within the transitional period. And EMA reviews the mock-ups submitted with a centralised transfer within 15 working days, with comments to be addressed before printing; specimens are needed only where the overall pack design changes.

Change only what the transfer allows

The transfer application covers holder and local representative details and nothing else. Artwork agencies often take the opportunity to refresh a layout or correct wording, and each such change needs its own regulatory basis. Compare every revised component with the approved text before it goes to print, and treat any difference outside the holder block as a finding.

Fees and planning across many markets

The unit of work in a transfer is the authorisation, not the product. A centralised product is one application and one EMA fee. A product authorised through a DCP in fifteen Member States is fifteen national applications and fifteen fees set by fifteen authorities, and often more than one authorisation number per country where strengths are licensed separately. Budgeting from a product count rather than an authorisation count is the usual reason transfer budgets overrun.

Read more about Fees and planning across many markets

A workable sequence for a multi-market transfer runs as follows.

  • Build the inventory: every authorisation number, route, Member State, holder entity, renewal date, marketing status and open procedure in scope.
  • Clear the queue: close or schedule pending variations, and decide who files anything that cannot wait.
  • Fix the pharmacovigilance handover: QPPV, master file, safety data exchange agreement and the date the safety database moves.
  • Agree dates with the authorities that will commit to one, starting with EMA's implementation date, and plan around the Member States that take longest.
  • File the transfers, the MRP variation for the pharmacovigilance system summary and any name-change variations in parallel, cross-referenced, and notify the reference Member State.
  • As each approval arrives, update the Article 57 data within 30 days, switch the artwork for that market and record the last batch released under the old holder.

The inventory decides the outcome. Deals are negotiated per product and per brand, while authorities work per authorisation number, and the gap between the two lists is where forgotten strengths, dormant licences and duplicate authorisations hide.

Common mistakes

  • Filing a variation for a change of legal entity, or a transfer for a change of name. The first is not valid; the second spends months and fees on a change that a Type IA IN notification covers.
  • Assuming one EU procedure for an MRP or DCP product, or promising a single closing date in the sale agreement. Each concerned Member State needs its own application and approves on its own day.
  • Leaving the pharmacovigilance system until after approval. The QPPV and the system summary are part of the application, and the MRP variation for the summary is required unless the same master file continues within the same group.
  • Bundling other product information changes into the transfer, or missing a product name that contains the old holder's name and needs its own variation.
  • Updating the Article 57 record late. The 30 days run from the approval of the transfer, not from the implementation date or the first batch in new packs.
  • Overlooking the sunset clause on dormant licences bought for a later launch. The three years keep running through the transfer.

What the agreed 2026 EU pharma package changes

The transfer procedure itself is not a focus of the pharma package adopted by the Council on 28 September 2026, which is not yet in force, and the rules described above remain the ones to file under. One provision does give transfers a new role. Under Article 120(4) of the agreed regulation, a holder that intends to withdraw a critical medicine or a priority antimicrobial must first publicly offer to transfer the marketing authorisation or to grant a letter of access to the dossier. A withdrawal decision for such a product would therefore start with a search for a transferee. Our page on shortage prevention under the agreed package covers the notice periods around it.

The package also changes obligations that a new holder inherits, including unlimited validity by default, a revised PSUR schedule and electronic product information. The overview of the ten main changes lists them, and the legislative timeline tracks when they will apply. For a transfer agreed now and completed after the new rules apply, the due diligence list should include which of those obligations will fall on the buyer.

Put this guide to work

The jobs in the Regunaut platform that apply what this guide covers to your own product.

Terms used in this guide

Common questions

MAH transfers: what teams ask

What is the difference between an MAH transfer and a change of MAH name?

A transfer moves the authorisation to a different legal entity and falls outside the Variations Regulation (Article 1(2) of Regulation (EC) No 1234/2008). A change of name or address where the legal entity stays the same is a Type IA IN variation, category E.4(a) in the 2025 classification guidelines. The applicant must declare which case applies.

How long does an MAH transfer take?

For a centrally authorised product EMA issues its opinion within 30 days of receiving a valid application, and the Commission then amends the decision; the implementation date can be set up to six months after that decision is notified. National timelines vary by Member State. The Dutch authority, for example, processes a change of holder within 60 days and does not guarantee a date.

Who submits the transfer application, the seller or the buyer?

Under Regulation (EC) No 2141/96 the current holder submits the application to EMA, with declarations signed by both parties. Most national authorities also expect the current holder to apply. Some, such as the Dutch Medicines Evaluation Board, accept an application from the future holder if the current holder authorises it in writing.

Is an MAH transfer for an MRP or DCP product handled by the reference Member State?

No. The CMDh treats the transfer as an independent, purely national application in each Member State, with national fees and national management. The current holder notifies the reference Member State which concerned Member States and holders are involved. Only the accompanying variations, such as the new pharmacovigilance system summary, run through the MRP.

Can stock with the old holder's name still be sold after the transfer?

Generally yes, within limits. For centralised products, batches carrying the previous holder's name may still be released by agreement during a transitional period of up to six months, and packs already on the market may remain. National authorities set their own periods; Croatia, for example, allows up to 18 months, shelf life permitting.

Does the new holder need its own QPPV and PSMF before the transfer?

Yes. Details of the qualified person for pharmacovigilance and the summary of the pharmacovigilance system in the new holder's name are part of a centralised transfer application. For MRP and DCP products the summary is submitted by a Type IA IN variation to all Member States concerned, unless the same master file continues within the same group.

Sources

Article numbers refer to the Council's position at first reading of 28 September 2026 (ST 7106/2/26 REV 2 for the directive, ST 7105/2/26 REV 2 for the regulation), which reflects the political agreement of December 2025. Numbering may change in the act published in the Official Journal.

  1. EUR-Lex: Commission Regulation (EC) No 2141/96 concerning the examination of an application for the transfer of a marketing authorization for a medicinal product falling within the scope of Council Regulation (EEC) No 2309/93
  2. European Medicines Agency: Transfer of marketing authorisation: questions and answers
  3. CMDh: Q&A list for the submission of variations according to Commission Regulation (EC) No 1234/2008 (CMDh/132/2009, Rev. 66, June 2026), question 2.8 on transfers and Article 1(2)
  4. EUR-Lex: Directive 2001/83/EC on the Community code relating to medicinal products for human use, consolidated text, Articles 8(2), 54, 55, 59 and 104
  5. European Medicines Agency: Reporting requirements for marketing-authorisation holders (Article 57 data, 30 calendar days for transfers)
  6. Medicines Evaluation Board (CBG-MEB), Netherlands: Question and answer document concerning changes not covered by Variation Regulation 1234/2008 (version 3 September 2026)
  7. HALMED, Croatia: Transfer of marketing authorisation, instructions for applicants
  8. Council of the EU: Position at first reading on the Regulation laying down Union procedures for the authorisation and supervision of medicinal products, adopted 28 September 2026 (ST 7105/2/26 REV 2)
  9. Council of the EU: 'Pharma package': Council and Parliament reach a deal (press release, 11 December 2025)
  10. Council of the EU: The pharma package, new EU rules on medicines (policy page)
  11. European Commission: Reform of the EU pharmaceutical legislation
  12. EUR-Lex: Procedure 2023/0132/COD, Directive on the Union code relating to medicinal products for human use (COM(2023) 192)
  13. EUR-Lex: Procedure 2023/0131/COD, Regulation on Union procedures for the authorisation and supervision of medicinal products (COM(2023) 193)

Run the transfer from one licence timeline

Atlas shows which authorisations move, market by market, with the renewals, variations and fees due on each. Print ProofReader checks the revised packs against the approved text.

Open your portfolio in Atlas

Put the licences in scope on one timeline by product and market, and see what is due on each while the transfer runs.

Try for free

Walk through a transfer with us

30 minutes on your products and markets: the authorisations in scope, the procedures open on them and the artwork that has to change.

Book a demo